3D Medicines Inc.
思路迪医药股份有限公司
(Incorporated in the Cayman Islands with limited liability)
(Stock Code: 1244)

VOLUNTARY ANNOUNCEMENT
SIGNIFICANT BREAKTHROUGH ACHIEVED IN THE DEPLOYMENT OF "AI + mRNA" CANCER VACCINE STRATEGY

This announcement is made by 3D Medicines Inc. (the "**Company**", together with its subsidiaries, the "**Group**") on a voluntary basis.

The board of directors of the Company (the "**Board**") is pleased to announce that the key component of the ionizable cationic lipid in the lipid nanoparticles (LNP) for nucleic acid drug delivery, independently developed by the Company, has recently been filed for a patent under the Patent Cooperation Treaty (PCT).

By utilizing AI (artificial intelligence) to design and screen hundreds of lipid compounds, we have established an ionizable cationic lipid research and development platform targeting different cell types and organs. This platform efficiently synergizes with the development of our self-developed mRNA cancer vaccine projects, breaking through delivery technology barriers, improving drug targeting, addressing challenges such as non-specific tissue distribution, enhancing drug development efficiency, and building a differentiated competitive advantage for our products.

By order of the Board
3D Medicines Inc.
Dr. Gong Zhaolong
Chairman of the Board and Executive Director

Hong Kong, March 11, 2025

As at the date of this announcement, the Board of Directors of the Company comprises Dr. GONG Zhaolong as executive Director, Mr. ZHU Pai, Mr. ZHOU Feng and Ms. CHEN Yawen as non-executive Directors, and Dr. LI Jin, Dr. LIN Tat Pang and Mr. LIU Xinguang as independent non-executive Directors.